Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company developing novel prophylactic antibody-based therapeutics for rare bleeding and thrombotic disorders, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead asset, sutacimig (HMB-001), has received FDA Breakthrough Therapy Designation, and the company raised $301.5 million in a US IPO backed by investors including Novo Holdings and RA Capital Management.